Miguel Meza

TL;DR: In this article, a triple-gene-edited induced pluripotent stem cell (iPSC) line was generated to express a high affinity, non-cleavable version of the Fc receptor CD16a and a membrane bound interleukin (IL)-15/IL-15R fusion protein.

TL;DR: In long term killing assays, FT596 alone demonstrated equivalent levels of CD19 targeted anti-tumor activity as primary CD19-targeted CAR (CAR19) T cells when tested against CD19+ CD20+ B lymphoblast target cells and demonstrated enhanced levels of activity when used in combination with anti-CD20 (rituximab).

TL;DR: A multiplexed edited base iPSC-derived NK (iNK) cell configuration capable of multiantigen-specificity through combinatorial use of CAR and hnCD16 with monoclonal antibodies to tackle antigen escape is developed, demonstrating the versatility of FT576 as a highly effective multi-antigen targeting platform.

TL;DR: Pre-clinical data for FT819, a first-of-kind off-the-shelf human induced pluripotent stem cell (hiPSC)-derived CAR T cell product, shows that TRAC-iT possess a potent cytotoxic T lymphocyte response to CD19 antigen challenge in a similar manner to peripheral blood CAR T cells as demonstrated by expression of markers indicative of degranulation.